beta-hydroxysteroid dehydrogenase — tissue specific protector of the mineralocorticoid receptor.


**The voltage-gated K+ channel subunit Kv1.1 links kidney and brain**

David H. Ellison1,2

1Division of Nephrology & Hypertension, Department of Medicine, Department of Physiology & Pharmacology, and Heart Research Center, Oregon Health & Science University, Portland, Oregon, USA. 2VA Medical Center, Portland, Oregon, USA.

**Analysis of Mendelian Mg2+ wasting disorders helps us to unravel the mechanisms of Mg2+ homeostasis. In this issue of the JCI, Glaudemans and colleagues show that mutations in voltage-gated K+ channel subtype 1.1 (Kv1.1) cause autosomal dominant hypomagnesemia in humans (see the related article beginning on page 936). Interestingly, other mutations in the same protein cause the neurological disease episodic ataxia type 1. The authors show, using cells with heterologous expression of the wild-type and mutant channels, that the mutant channel is dysfunctional and speculate that Mg2+ wasting results from changes in apical membrane voltage along the nephron. Mechanisms by which the apical voltage is generated and how Kv1.1 fits within this context are discussed herein.**

Rare Mendelian diseases are windows into both physiology and pathogenesis. Examples include the rare Mg2+ wasting disorders that form the basis for most of our current understanding of renal Mg2+ transport. Several proteins that mediate Mg2+ transport, both around and through cells, have now been identified and cloned, using positional cloning approaches. Secondary dysfunction of these proteins may also contribute to hypomagnesemia in the critically ill, where the incidence has been estimated as 20%–60% and is associated with excess mortality (1). Hypomagnesemia is often drug related, with diuretics, calcineurin inhibitors, and antineoplastic agents (e.g., cisplatin and cetuximab) common offenders (2). The study of Mendelian disorders of Mg2+ homeostasis has also led to the identification of novel and sometimes unexpected regulatory pathways that impact transport pathways secondarily. Eighty percent of plasma Mg2+ is ultrafilterable by glomeruli. Whereas the majority of every other ion studied to date is reabsorbed along the proximal tubule, proximal Mg2+ reabsorption constitutes only 10%–15% of the filtered load. In contrast, the thick ascending limb (TAL) reabsorbs approximately 70% of filtered Mg2+ and clearly plays a central role in regulating Mg2+ excretion. What surprised many investigators, however, was that most disorders of Mg2+ balance result from dysfunction along the distal convoluted tubule (DCT), a short nephron segment that, just a few years ago, was believed to play only a minor role in Mg2+ homeostasis (3). The DCT is now recognized as important not only for Mg2+ balance, but also for the control of Na+, K+, and Ca2+ levels (4).

In this issue of the JCI, Glaudemans and colleagues report that missense mutations in K+ voltage-gated channel, Shaker-related subfamily, member 1 (KCNA1), which encodes voltage-gated K+ channel subtype 1.1 (Kv1.1) expressed by DCT cells, causes autosomal dominant hypomagnesemia in humans (5). Surprisingly, other mutations in the same gene cause episodic ataxia type 1 (EA1) (6), a neurological syndrome in which hypomagnesemia has not been reported. In the present study, the investigators showed that Kv1.1 localizes to the apical membrane of DCT cells, where the transient receptor potential cation channel, subfamily M, member 6 (TRPM6) controls Mg2+ entry, driven by its electrochemical potential. Expression studies showed that the mutated Kv1.1 protein, while having no direct effect on TRPM6, exhibited reduced

**Conflict of interest:** The author has declared that no conflict of interest exists.

**Nonstandard abbreviations used:** CNT, connecting tubule; DCT, distal convoluted tubule; ENaC, epithelial Na+ channel; KCNA1, K+ voltage-gated channel, Shaker-related subfamily, member 1; Kv1.1, voltage-gated K+ channel subtype 1.1; ROMK, renal outer medullary K+ channel; TAL, thick ascending limb; TRPM6, transient receptor potential cation channel, subfamily M, member 6.

**Citation for this article:** J. Clin. Investig. 119:763–766 (2009), doi:10.1172/JCI38835.
K⁺ permeability (conductance), compared with the wild-type channel. The investigators therefore postulate that disease-causing defective K⁺ channels depolarize the apical membrane of DCT cells, reducing the electrical driving force favoring Mg²⁺ entry, leading to renal Mg²⁺ loss.

**Mg²⁺ transport and transepithelial voltage**

Years before ion transport proteins expressed by DCT and TAL were identified at the molecular level, micropuncture and microperfusion studies provided important details about the electrophysiology of these nephron segments. The lumen is electrically positive along the TAL, with respect to the interstitium (Figure 1), whereas it is electrically negative along the last portion of the DCT (Figure 1) and remains negative along the connecting tubule (CNT) and collecting duct (not shown). The transepithelial voltage drives ion movement throughout the nephron. Along the TAL, the lumen positive voltage drives Ca²⁺, Mg²⁺, and, at least along part of the segment, Na⁺ absorption across paracellular pathways; along the CNT and collecting duct, the lumen negative voltage drives K⁺ secretion, primarily via the renal outer medullary K⁺ channel (ROMK) (7). Along part of the DCT, the transepithelial voltage becomes an impediment to absorption. To complicate matters further, the magnitude of the transepithelial voltage along the DCT increases whenever circulating levels of the hormone aldosterone rise (11), as during depletion of the extracellular fluid volume. Clearly, if there were substantial paracellular permeability for divalent cations along these segments, Mg²⁺ would not be reabsorbed; although the initial report suggested that claudin 16 (formerly paracellin-1) is expressed by the DCT (12), expression levels must be very low, because substantial paracellular transport does not occur.

**Figure 1**

Schematic diagram of the anatomy, molecular pathways, and electrophysiology of Mg²⁺ transport along the distal nephron. Top panel: Nephron segmentation, including the TAL and the DCT subsegments DCT1 and DCT2. Note that the transition from DCT1 to DCT2 is gradual. Middle panel: Transport pathways in these segments include Na⁺/K⁺-ATPase (−), the furosemide-sensitive Na⁺K⁺2Cl⁻ cotransporter (NKCC2), the Cl⁻ channel (CLCNKB), the epithelial Na⁺ channel (ENaC), and the thiazide-sensitive NaCl cotransporter (NCC). Mg²⁺ transport along the TAL is primarily paracellular. Along the DCT, however, it is mediated by TRPM6. Two K⁺ channels are present in the apical membrane: ROMK and, as shown by Glaudemans et al. in this issue of the JCI (5), Kv1.1 (see text for further details). K⁺ and Cl⁻ can exit DCT cells via a coupled K⁺/Cl⁻ cotransporter (KCC4) or a discrete K⁺ channel. Lower panel: Membrane voltages along each segment, in millivolts (mV). The basolateral voltage is similar in each cell type. V_TE, transepithelial voltage. As postulated by Glaudemans et al. (5), a defective Kv1.1 (indicated by red X) should depolarize the apical membrane (red bars) along the DCT, leading to hyperpolarization of the transepithelial voltage.
Mg2+ and K+ channels in the distal nephron

The conundrum for Mg2+ (and Ca2+) (i.e., how to achieve reabsorption against an electrochemical gradient) is solved by a change in absorptive route, from paracellular to transcellular (Figure 1). This difference corresponds to the appearance of transient receptor potential channels that mediate Mg2+ uptake by DCT cells. In the case of Mg2+, TRPM6, perhaps in association with TRPM7, plays this role (13); in the DCT, however, the voltage that drives ion movement is not the transepithelial voltage, but the voltage across the apical membrane (Figure 1), which is oriented with the cell interior being negative, with respect to apical fluid.

Glaudemans et al. (5) could not detect a direct effect of mutant Kv1.1 on TRPM6 in a heterologous expression system and therefore postulate that Mg2+ wasting is indirect, a result of depolarization of the apical membrane of DCT cells (Figure 1; see also Figure 4 in ref. 5). This provocative hypothesis is consistent with their data, which show that cells transfected with wild-type Kv1.1 display a transmembrane voltage near –50 mV, whereas cells transfected with mutant Kv1.1 do not. It also, however, raises intriguing questions for future study. Figure 4 in the Glaudemans et al. study (5) shows apical pathways for Mg2+ and K+ in a model DCT cell. Figure 1 herein incorporates several additional pathways into a model of the TAL and DCT and emphasizes some complicating features. First, a second K+ channel, ROMK, is expressed throughout the distal tubule (14). Second, the major apical depolarizing current in DCT2 (and CNT) is carried by Na+ through the epithelial Na+ channel (ENaC). Third, the voltage across any membrane will be determined largely by ionic concentration differences, factored by the relative conductance to each ion. In most models of DCT and CNT function, the K+ conductance is generated predominantly by ROMK (7).

The model postulated by Glaudemans et al. to account for Mg2+ wasting in the disease setting (see Figure 4 in ref. 5) suggests that a dysfunctional Kv1.1 causes apical depolarization (note the red bars in Figure 1). This assumes that Kv1.1 contributes importantly to apical conductance, at steady state, together with ENaC and ROMK and implies that its dysfunction causes, in addition to apical depolarization, an increase in the magnitude of transepithelial voltage. Because ROMK is expressed by DCT cells (14), apical depolarization would enhance K+ secretion, which should generate a phenotype similar to that of Gitelman syndrome, with K+ and Mg2+ wasting; this is not typical for patients with autosomal dominant hypomagnesemia. The expression studies reported by Glaudemans et al. used nonpolared cells that do not express most of the solute transport proteins of the distal nephron, so the membrane depolarization hypothesis could not be tested directly. Future work could perhaps address this issue by knocking a mutant KCNAI gene into mice. Another puzzling issue for future study is the observation that distinct mutations in nearby amino acid residues of KCNAI generate phenotypes that reflect dysfunction in two different organs (brain and kidney). One possible reason is that Kv1 subunits are (probably) never made into homo-meric channels. They partner with other Kv1 subunits to constitute the functional tetrameric channel. In brain, Kv1 subunits coassemble with Kv1.2 and Kv1.4. In addition, they also coassemble with a variety of β subunits, and the complement of partners, both pore-forming α subunits and auxiliary β subunits, dictates the functional characteristics of the channels (15). Therefore, the composition of channels containing Kv1.1 in kidney and brain may well be different, and in the context of these tissue-specific heteromeric assemblies, mutations even at close locations within the protein exert their effects in a tissue-specific manner, giving rise to distinct physiological abnormalities.

Rare diseases and common syndromes

Inherited Mg2+ wasting is rare, but the current results (5) help to explain hypomagnesemia in several relatively common clinical situations. Patients with heart failure commonly suffer from Mg2+ wasting (16), perhaps owing to aldosterone excess and chronic loop diuretic use. Both factors depolarize the apical membrane of DCT2 cells just as in the postulated model of Kv1.1 dysfunction. cisplatin treatment also depolarizes the apical membrane, thereby enhancing Mg2+ and K+ excretion (17). Conversely, drugs that block aldosterone or ENaC represent the only effective approach to inhibiting renal Mg2+ wasting in most clinical situations (18). These drugs enhance the driving force favoring Mg2+ reabsorption, by hyperpolarizing the apical membrane of DCT cells. Discoveries such as the one reported in this issue by Glaudemans et al. will continue to illuminate pathophysiology; they also emphasize that mechanisms of ion transport are shared in kidney and brain, and in epithelial and nonepithelial cells.

Acknowledgments

The author appreciates helpful comments on the manuscript by John P. Adelman (Vollum Institute, Oregon Health & Science University) and useful discussions with Heino Velázquez (Yale University) and Paul Welling (University of Maryland). Work in the author’s laboratory is supported by the NIH (DK51496) and by a Merit Review from the US Department of Veterans Affairs.

Address correspondence to: David H. Ellison, Division of Nephrology & Hypertension, Oregon Health & Science University, 3314 SW US Veterans Hospital Road, Portland, OR 97239, USA. Phone: (503) 494-7159; Fax: (503) 494-5330; E-mail: ellisond@ohsu.edu.

Myoglobin tames tumor growth and spread

Ulrich Flögel1 and Chi V. Dang2

1Institut für Herz- und Kreislaufphysiologie, Heinrich-Heine-Universität, Düsseldorf, Germany. 2Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA.

Tumor growth is accompanied by tissue hypoxia, but does this reduced oxygen availability promote further tumor expansion, resulting in a vicious cycle? In this issue of the JCI, Galluzzo et al. report that increasing oxygen tension in tumor cells by ectopically expressing the oxygen-binding hemoprotein myoglobin indeed affects tumorigenesis (see the related article beginning on page 865). Tumors derived from cells transfected with myoglobin grew more slowly, were less hypoxic, and were less metastatic. These results will spur further mechanistic inquiry into the role of hypoxia in tumor expansion.

Tumorigenesis involves not only cell autonomous genetic alterations that result in activation of oncogenes and loss of tumor suppressor genes but also adaptation of neoplastic cells to the tumor microenvironment. Although the activation of oncogenes and their products MYC, AKT, PI3K, and RAS as well as the loss of p53 and VHL tumor suppressors have been linked to altered tumor metabolism, it has become apparent that the hypoxic tumor microenvironment, which activates the low oxygen–sensing HIF transcription factors, also plays a key role in tumor metabolism and tumorigenesis (1). It is well documented that new blood vessels recruited into a growing tumor mass are disorganized (2), often culminating in vascular “dead-ends” rather than providing the canonical microvasculature characteristic of normal tissue, in which arterioles are connected to venules via a capillary bed. Hence, tumors endure significant hypoxia that is distributed heterogeneously within a tumor mass, and areas of tumor hypoxia could fluctuate with time (3). In this regard, whether tumor hypoxia itself contributes to tumor progression has been a matter of debate rather than of experimentation.

Transduction of myoglobin to improve tumor oxygenation

In this issue of the JCI, Galluzzo et al. (4) present an innovative and elegant approach to addressing the question of whether hypoxia is a side effect of or a key player in tumor progression. The authors used lentiviral vector–mediated transduction to achieve expression of myoglobin (Mb) in human lung carcinoma cells as a genetic tool to prevent tumor hypoxia. Like its molecular relative hemoglobin, Mb — a cytosolic hemoprotein present in skeletal and heart muscle (5) — reversibly binds O2 and thus facilitates O2 transport from the blood to mitochondria during periods of increased metabolic activity or serves as an O2 reservoir under hypoxic conditions (Figure 1). Transduced cancer cells expressing Mb showed no signs of altered cellular proliferation in vitro, but, surprisingly, in vivo xenograft growth was severely diminished after injection of transduced cells into mice. The data reported by Galluzzo and coworkers are quite impressive: presence of Mb resulted in a 5-fold decrease in tumor expansion compared with controls. Furthermore, the expression of Mb suppressed both local and distal metastatic spread, led to enhanced cancer cell differentiation, and reduced the degree of abnormal vascularization. The authors also report that the expression of HIF-1α, which is generally accepted as a master regulator of the cellular hypoxic response, was downregulated in Mb-expressing cancer cells. The data suggest that the beneficial effects of the presence of Mb within cancer cells are the result of improved O2 delivery to the tumor, which “calms” the tumor’s craving to expand.

Globins, oxygen, and beyond

Beyond the initial finding of Mb’s O2-binding properties — set into a physiological context especially by the seminal work of Beatrice and Jonathan Wittenberg — within the last decade, the field of globin biology was invigorated, particularly by the generation of gene-deficient mutants but also by the discovery of two new members of the globin family, cytoglobin (Cb) and neuroglobin (reviewed in refs. 5–8). Based on this recent work, the role of Mb in muscle physiology has been reassessed and its scope of function has been considerably extended beyond oxygen storage and delivery to also include a role as an important scavenger of NO and ROS, signaling molecules involved in cellular oxidative stress (Figure 1). Appreciating the diversity of Mb’s properties, Galluzzo et al. (4) used mutated forms of Mb unable to bind O2 to demonstrate that the inhibition of tumor progression is primarily caused by improved O2 delivery. However, it should be kept in mind that structural alterations at Mb’s heme-binding pocket will also alter the in vivo kinetics for all other events taking place at this site, including radical reactions. It is, therefore, tempting to speculate that these newly uncovered properties of Mb may

Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: Cb, cytoglobin; Mb, myoglobin.

Citation for this article: J Clin Investig. 119:766–768 (2009). doi:10.1172/JCI38796.